News

Video

Part 2: Biggest innovations in ophthalmology in 50 years

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Kelly Donovan, MD:

This precedes my time, but I think probably, from what I understand, OCT, I would agree. Optical coherence tomography probably changed our ability the most to see diseases, categorize them appropriately, and then determine who needs treatment. But I think what revolutionized treatment the most thereafter would be the anti-VEGF agent, the biologics. So now, with those 2 innovations, we're able to identify the correct patient and give them the correct treatment to help save vision. And I think we've been able to do that for a huge, huge number of people across the world.

Nita Valikodath, MD, MS:

So I think one of the biggest advances is the advances in imaging techniques that we have. We now have portable handheld OCT devices. We have fundus photos with [fluorescein angiography, or] FA and OCT capabilities combined. We are coming out with other advances in OCT findings at the University of Michigan that hopefully will be on the pipeline soon. So I do think in retina overall, and especially in pediatrics, we are advancing in our imaging capabilities, which allow us to diagnose and manage patients better.

Oleg Alekseev, MD, PhD:

I think probably the development of OCT, optical coherence tomography, is, I would say, certainly at the top there. It is a very rapid, very information-rich testing modality that's noninvasive, relatively inexpensive, gives us an entirely new insight into retinal diseases. So that would be my choice on the diagnostic side of things. And then, of course, being a specialist in inherited retinal diseases, I'm biased toward that field. And so I would say that the development and FDA approval of Luxturna's gene therapy for RPE65 associated retinal degenerations is absolutely the biggest breakthrough, at least in my part of the ophthalmology field.

Tania Tai, MD:

I think there have been so many innovations over the past 50 years, it's hard to really name just one. I think one game changer, and that was not something recent, is laser trabeculoplasty, because it really opened a new venue of treatment for patients that can be done in the office setting. It's safe, it's efficacious, and it can be first-line treatment for patients as well. Of course, now we have the many other innovations like MIG surgeries or minimally-invasive bleb surgeries, as well as the medications that I mentioned before that I'm very excited about, things that can be implanted or injected. But I think laser trabeculoplasty definitely ranks amongst ones of the top, one of the top innovations in the past 50 years.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.